Lotus Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LTUS research report →
Price Chart
About the company
Lotus Pharmaceuticals, Inc. currently has no substantial business activities. Headquartered in Nashville, Tennessee, the company previously focused on the development, production, and distribution of pharmaceutical products within the People's Republic of China.
- CEO
- Zhong Yi Liu
- IPO
- 2005
- Employees
- 233
- HQ
- Irvine, CA, US
Get TickerSpark's AI analysis on LTUS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $104.26K
- P/E
- -333.36
- PEG
- -3.33
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- -3.46
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 0.00%
- ROIC
- 0.00%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-29,031
- Net Income
- $-29,031-126.2%
- EPS
- $0.00+0.0%
- OCF Growth
- +0.0%
- FCF Growth
- +0.0%
- 52W High
- $0.01
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -1.60
- RSI (14)
- 63
- Avg Volume
- 6.61K
No earnings-call transcripts are available for LTUS yet.
- Free Float
- 50.8%
- Shares Outstanding
- 27.44M
- Float Shares
- 13.94M
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 21, 07 | WASSERMAN ADAM C | other | 50,000 |
| May 31, 07 | WASSERMAN ADAM C | other | 44,200 |
| Jan 6, 04 | NIERENBERG DAVID | other | 25,000 |
| Nov 22, 02 | NIERENBERG DAVID | buy | 7,500 |
| Oct 18, 01 | NIERENBERG DAVID | buy | 10,000 |
| Aug 25, 03 | NIERENBERG DAVID | other | 41,700 |
| Aug 25, 03 | NIERENBERG DAVID | other | 41,700 |
| May 1, 03 | NIERENBERG DAVID | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our LTUS coverage
Recent articles, reports, and earnings notes.
No research on LTUS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LTUS report →